Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04478708 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity
A Phase 1 study of Obesity, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
- 3
- Study locations
NCT04478708 is a Phase 1 study of Obesity that has completed, run by Amgen. The registered enrollment target is 110 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04478708, a Phase 1 study of Obesity, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
- 3
- Study locations
Study Summary
The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL maridebart cafraglutide
Study Locations (3)
California
- Anaheim Clinical Trials - Anaheim
- Orange County Research Center - Tustin
Florida
- Clinical Pharmacology of Miami, LLC - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2020-08-07 |
| Est. Completion | 2022-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04478708
The ClinicalTrials.gov registry entry for NCT04478708 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04478708 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.
Frequently Asked Questions
What is clinical trial NCT04478708 about?
NCT04478708 is a clinical study titled "Single and Multiple Ascending Dose Study of AMG 133 in Participants With Obesity". The study aims to assess the safety and tolerability of maridebart cafraglutide as single and multiple doses in participants with obesity
What is the current status of trial NCT04478708?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2020-08-07. Estimated completion is 2022-11-18.
What conditions does trial NCT04478708 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT04478708?
The interventions under investigation include: Placebo (DRUG), maridebart cafraglutide (BIOLOGICAL).
Who is sponsoring clinical trial NCT04478708?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04478708 being conducted?
This trial has 3 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.